The future of preventive medicine starts here
Our mission is to develop targeted live biotherapeutics and molecular diagnostic tools that target the core drivers of diseases of high unmet medical need
See Our Pipeline
Developing better therapies through a deep understanding of human microbial ecology
As a leading developer of next-generation live biotherapeutic products, we combine clinical data, bioinformatics, and top-notch microbial science to develop synergistic combinations of bacteria that target diseases with high unmet medical need. By leveraging our proprietary Precision Symbiotics Platform™ and in-house GMP manufacturing capabilities, we have rationally designed microbial consortia to address medical conditions where the human microbiota plays a central role in disease prevention.
Our Platform

News
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
Series C – $12 Million
March 12, 2024
Read More

News
Siolta successfully doses first newborn in phase 2 study
Groundbreaking trial of STMC-103H for the prevention of atopic diseases
July 20, 2022
Read More

Publications
Microbial Genomics
Finding the right fit: evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data
Read More